ZX008 Expanded Access Program-Dravet Syndrome

Brief description of study

The treatment plan for this Expanded Access Protocol is for patients with Dravet syndrome who do not qualify for participation in one of the ongoing ZX008 (fenfluramine hydrochloride) clinical trials. This treatment uses an investigational drug named ZX008, fenfluramine hydrochloride. Investigational means that the Food and Drug Administration (FDA) has not approved the drug for this use. How well this investigational drug works or even if it is safe has not been proven through clinical trials.


Clinical Study Identifier: s19-01402
ClinicalTrials.gov Identifier: NCT03780127
Principal Investigator: Orrin Devinsky.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.